Quantum Dots in Biomedical Imaging and Drug Delivery

[1] Ali Raza Khan, [2] Fatima Zahra,[3] Hassan Shahid

[1] Department of Nanotechnology, University of Lahore, Lahore, Pakistan

[2,] Institute of Biomedical Sciences, Aga Khan University, Karachi, Pakistan

[3,] Department of Chemistry, Government College University, Lahore, Pakistan

***Corresponding Author :** aliraza.khan@uol.edu.pk

Abstract: *Quantum dots (QDs) are semiconductor nanocrystals with unique optical properties, making them invaluable tools in biomedical imaging and drug delivery applications. Their size-tunable fluorescence, high photostability, and surface modifiability enable precise cellular imaging and targeted therapy. This review explores the synthesis methods, functionalization strategies, and biomedical applications of QDs, focusing on their role in in vitro and in vivo imaging, drug delivery systems, and theranostics. Challenges such as toxicity, biocompatibility, and regulatory hurdles are discussed, along with strategies to mitigate these issues. The potential of QDs in personalized medicine and their future prospects in clinical settings are also highlighted.*

Keywords: *Quantum dots, biomedical imaging, drug delivery, nanomedicine, fluorescence, surface functionalization, theranostics, biocompatibility*

Introduction

Quantum dots (QDs) are nanometer-sized semiconductor particles that exhibit unique optical and electronic properties due to quantum mechanics. Their size-dependent fluorescence, high quantum yield, and photostability make them ideal candidates for various biomedical applications, including imaging and therapy. The ability to functionalize QDs with specific ligands allows for targeted delivery of therapeutic agents, enhancing the efficacy and specificity of treatments. Despite their promising applications, challenges related to toxicity, biocompatibility, and regulatory approval remain significant hurdles in translating QD-based technologies into clinical practice.

Synthesis and Characterization of Quantum Dots

Quantum dots (QDs) can be synthesized using various methods, each offering distinct advantages in terms of size control, surface functionalization, and scalability.

1. **Colloidal Synthesis:**

   Colloidal synthesis is one of the most widely used techniques for producing quantum dots due to its simplicity and cost-effectiveness. In this method, precursor materials such as metal salts (e.g., cadmium or lead) are dissolved in a solvent and then reacted under controlled temperature and pressure conditions. The reaction leads to the formation of quantum dots, which are typically stabilized by surface ligands to prevent aggregation. The size of the QDs can be precisely controlled by adjusting the reaction time and temperature, allowing for fine-tuning of their optical properties.

2. **Chemical Vapor Deposition (CVD):**

Chemical vapor deposition is a more sophisticated method used for the large-scale production of quantum dots. This technique involves the deposition of gaseous precursors onto a heated substrate, where they react to form thin films or nanocrystals of quantum dots. CVD allows for high-quality quantum dots with excellent uniformity, but it is more complex and requires precise control over the deposition parameters. The method is often employed for applications that require high-quality, large-area quantum dots, particularly in optoelectronic devices.

3. **Biological Synthesis:**

   Biological synthesis of quantum dots is an emerging green chemistry approach that involves using biological organisms, such as bacteria, fungi, or plants, to produce quantum dots. These organisms can reduce metal salts into nanoparticles, which are then stabilized by proteins, peptides, or other biomolecules. This method is environmentally friendly, as it avoids toxic solvents and high temperatures typically required in traditional methods. Additionally, the biocompatibility of these biologically synthesized quantum dots makes them highly suitable for biomedical applications.

Characterization Techniques:

Once quantum dots are synthesized, their structural, optical, and electronic properties must be thoroughly characterized to ensure their suitability for specific applications.

1. **UV-Vis Spectroscopy:**

   Ultraviolet-visible (UV-Vis) spectroscopy is one of the primary techniques used to characterize the optical properties of quantum dots. It provides information about the absorption spectra, which reveals the bandgap of the quantum dots and their electronic transitions. The absorption spectra are highly dependent on the size and composition of the quantum dots, with smaller dots typically exhibiting a blue shift (absorption at shorter wavelengths) compared to larger dots. This technique helps in monitoring the growth and stability of QDs during synthesis.

2. **Fluorescence Spectroscopy:**

   Fluorescence spectroscopy is essential for investigating the emission properties of quantum dots. When excited by light at a specific wavelength, quantum dots emit light at a longer wavelength, a phenomenon known as fluorescence. This technique provides information on the emission peak, quantum yield, and photostability of the quantum dots. The fluorescence spectra can be used to determine the efficiency of energy transfer and the uniformity of the quantum dots, which are crucial parameters for their use in imaging and sensing applications.

3. **Transmission Electron Microscopy (TEM):**

   Transmission electron microscopy (TEM) is a powerful imaging technique used to analyze the size, shape, and morphology of quantum dots at the nanometer scale. TEM provides high-resolution images of individual quantum dots, allowing researchers to determine their size distribution, crystallinity, and any defects that may affect their properties. This

technique is particularly useful for confirming the synthesis of uniform quantum dots and assessing their structural integrity for various applications, including biological imaging and drug delivery.

Surface Functionalization and Bioconjugation of Quantum Dots

Surface functionalization and bioconjugation are crucial for enhancing the performance of quantum dots (QDs) in various applications, particularly in biomedicine, where they must interact with biological systems in a specific and controlled manner. These processes modify the surface of quantum dots to improve their stability, water solubility, biocompatibility, and targeting ability.

1. **Modification Strategies:**
    - **Ligand Exchange:**

      Ligand exchange is a process where the surface ligands (typically hydrophobic molecules) of quantum dots are replaced by more functional groups. This modification helps enhance the solubility of quantum dots in aqueous environments and enables the attachment of biomolecules, such as antibodies or peptides, for targeted delivery. Ligand exchange improves the stability of QDs in physiological conditions by preventing aggregation, a common issue in non-functionalized quantum dots. The new ligands can also provide specific functional groups that can further facilitate bioconjugation with biomolecules.

    - **Polymer Coating:**

      Polymer coating is another strategy for surface functionalization, where polymers are adsorbed or covalently attached to the surface of quantum dots. Polymers like polyethylene glycol (PEG) are often used due to their ability to enhance water solubility, reduce protein adsorption, and prolong the circulation time of quantum dots in vivo. The hydrophilic nature of polymer-coated quantum dots prevents aggregation and makes them more biocompatible, reducing potential toxicity. Additionally, polymer coatings can provide a platform for the conjugation of targeting agents, such as ligands or antibodies, which can direct the quantum dots to specific tissues or cells.

    - **Biomolecule Conjugation:**

      Biomolecule conjugation involves attaching biologically active molecules (e.g., antibodies, peptides, nucleic acids) to the surface of quantum dots. This conjugation is achieved by modifying the surface of quantum dots with functional groups that can covalently bond to biomolecules. The conjugation of biomolecules enables quantum dots to specifically bind to biological targets, such as receptors on cancer cells or pathogens. This functionalization improves the specificity of quantum dots for applications in targeted drug delivery, biosensing, and molecular imaging.

2. **Enhancing Water Solubility and Biocompatibility:**

One of the major challenges in utilizing quantum dots for biomedical applications is their poor solubility in aqueous environments. Surface functionalization plays a crucial role in overcoming this limitation.

- **Enhancing Water Solubility:**

  Quantum dots are typically synthesized in organic solvents, making them hydrophobic and limiting their use in biological systems. To address this, surface functionalization with hydrophilic ligands, such as PEG or other water-soluble polymers, significantly enhances their solubility in water. The hydrophilic coatings prevent the aggregation of quantum dots in aqueous solutions and make them stable in biological fluids, such as blood plasma. Furthermore, water-soluble quantum dots are more easily dispersed and less likely to precipitate, ensuring a uniform distribution in vivo.

- **Improving Biocompatibility:**

  Biocompatibility is crucial for the safe use of quantum dots in medical applications. The surface of quantum dots must be modified to reduce their toxicity and improve their interaction with biological systems. Polymer coatings, particularly PEGylation, play a significant role in reducing cytotoxicity by preventing the direct contact of the quantum dot core with biological tissues. Additionally, biomolecule conjugation allows for specific interactions with target cells, reducing non-specific uptake by healthy cells and tissues. The biocompatibility of quantum dots can also be improved by modifying their surface charge and size, both of which influence cellular uptake, circulation time, and potential immunogenicity.

Biomedical Imaging Applications of Quantum Dots

Quantum dots (QDs) offer significant advantages in biomedical imaging due to their unique optical properties, such as size-tunable fluorescence, high photostability, and broad absorption spectra. These properties make them versatile tools for both in vitro and in vivo imaging, facilitating high-resolution tracking of biological processes at the cellular and molecular levels.

1. **In Vitro Imaging:**

   - **Cell Labeling:**

     One of the most common applications of quantum dots in in vitro imaging is cell labeling. QDs can be used to label individual cells or subcellular components due to their excellent fluorescence properties. The surface of quantum dots can be modified with specific ligands, antibodies, or peptides that allow them to bind selectively to cellular markers. Once bound, QDs can be visualized under a fluorescence microscope, enabling researchers to monitor cell behavior, study cellular interactions, and track the uptake of substances by cells. Their high fluorescence quantum yield allows for clear, bright images with minimal background interference, making them ideal for long-term imaging studies.

   - **Intracellular Tracking:**

Quantum dots are also utilized for intracellular tracking, where they are employed to monitor the movement and localization of specific molecules or particles inside living cells. By attaching QDs to proteins, nucleic acids, or other intracellular components, researchers can trace their movement in real-time. The ability to track these movements within cells provides valuable insights into cellular processes such as signaling, protein trafficking, and vesicular transport. This tracking ability is particularly useful for studying dynamic cellular processes that involve changes in cellular structure or function over time.

2. **In Vivo Imaging:**

   - **Tumor Targeting:**

     Quantum dots play a crucial role in tumor targeting for in vivo imaging. Due to their tunable size and surface functionalization, QDs can be engineered to bind specifically to cancer cell markers or tumor-associated antigens. This selective targeting allows quantum dots to accumulate at the tumor site, where they can be visualized using fluorescence or other imaging modalities. By conjugating QDs with targeting ligands, such as antibodies or peptides, researchers can achieve high specificity and sensitivity in tumor detection, making quantum dots a powerful tool for early cancer diagnosis and monitoring therapeutic responses. Their small size also enables efficient penetration into tumor tissues, which is essential for effective imaging.

   - **Organ-Specific Imaging:**

     Quantum dots are also used for organ-specific imaging, where they can be designed to target specific organs or tissues in the body. By modifying the surface of QDs with ligands that bind to specific receptors expressed in particular organs, researchers can selectively target and visualize these tissues. For example, QDs can be functionalized to bind to endothelial cells for vascular imaging, or to liver-specific receptors for liver imaging. This capability enables high-resolution imaging of internal organs, providing valuable insights into tissue morphology, vascular dynamics, and organ function. Additionally, quantum dots can be used to study drug distribution and pharmacokinetics in different organs.

3. **Multimodal Imaging Approaches:**

   Multimodal imaging combines two or more imaging techniques to provide more comprehensive and accurate information about biological systems. Quantum dots are particularly well-suited for multimodal imaging due to their ability to be integrated with other imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET).

   - **Combining Fluorescence with Other Imaging Modalities:**

     Quantum dots can be combined with techniques like MRI or CT to create hybrid imaging systems. For instance, QDs can be used for fluorescence-based imaging of tumors, while MRI can provide detailed anatomical images of the same region. This

combination allows for both high-resolution molecular-level imaging and precise anatomical localization, improving the accuracy of diagnosis and treatment monitoring. In PET imaging, quantum dots can be conjugated with radiolabels to enable simultaneous molecular imaging and functional analysis.

- **Enhanced Sensitivity and Specificity:**

  The use of QDs in multimodal imaging enhances both sensitivity and specificity, as their fluorescence can provide real-time imaging at the cellular level, while other imaging modalities can provide structural information. This approach is particularly useful in cancer research, where early detection and precise localization of tumors are critical. Multimodal imaging also enables the study of complex biological processes in vivo, such as drug delivery, cell migration, and disease progression, with higher spatial and temporal resolution.

Quantum Dots in Drug Delivery Systems

Quantum dots (QDs) have emerged as promising candidates in drug delivery systems due to their unique optical properties, size-dependent fluorescence, and ability to be surface-functionalized for targeted drug delivery. Their application in drug delivery offers significant advantages, including enhanced therapeutic efficacy, reduced side effects, and real-time tracking of drug distribution within the body. Quantum dots can be engineered to carry drugs and release them in a controlled manner, providing a more targeted and efficient delivery system for various diseases, including cancer.

1. **Mechanisms of Drug Loading and Release:**

   - **Drug Loading:**

     Quantum dots can encapsulate drugs or therapeutic agents within their core or attach them to their surface through covalent or non-covalent interactions. The drugs can be loaded into quantum dots in several ways:

     - **Hydrophobic Interactions:** Hydrophobic drugs can be loaded onto the surface or into the core of quantum dots via hydrophobic interactions. These drugs are typically poorly soluble in water, and the quantum dot surface can be modified with hydrophobic ligands that allow for efficient loading and retention of the drug.

     - **Electrostatic Interactions:** Charged drugs can be loaded onto the quantum dots through electrostatic interactions. For example, negatively charged drugs can interact with positively charged quantum dots, ensuring stable drug binding.

     - **Covalent Bonding:** Some drugs are covalently attached to the surface of quantum dots using specific chemical linkers. This method provides more controlled release of the drug and prevents early leakage.

   - **Drug Release:**

Drug release from quantum dots can be controlled by various external and internal stimuli. The mechanisms of release are primarily designed to achieve targeted, controlled, and sustained delivery to specific tissues or cells.

- **Stimuli-Responsive Release:** Quantum dots can be engineered to release their payload in response to changes in the local environment, such as pH, temperature, or the presence of specific enzymes. For instance, in the acidic environment of tumor tissues or in intracellular compartments like lysosomes, QDs can release their drug payload, allowing for localized drug delivery.

- **Diffusion-Controlled Release:** The release of drugs can also occur through diffusion mechanisms, where the drug gradually diffuses out of the quantum dot carrier over time. This is typically used for drugs that require slow and sustained release over an extended period.

2. **Targeted Delivery Strategies:**

Quantum dots offer significant potential in achieving targeted drug delivery, which minimizes off-target effects and enhances therapeutic efficacy. The surface of quantum dots can be functionalized with targeting ligands, antibodies, peptides, or small molecules that recognize specific receptors or biomarkers on target cells or tissues.

- **Receptor-Mediated Endocytosis:**

One of the most common strategies for targeted drug delivery using quantum dots is receptor-mediated endocytosis. In this approach, quantum dots are functionalized with ligands or antibodies that specifically bind to cell surface receptors overexpressed on target cells, such as tumor cells. After binding, the QDs are internalized by the target cells via endocytosis. Once inside the cells, the quantum dots can release their drug payload in response to specific intracellular conditions, such as a decrease in pH or the presence of certain enzymes, thereby achieving localized drug delivery.

  - **Example:** In cancer therapy, quantum dots functionalized with monoclonal antibodies targeting specific tumor antigens can deliver chemotherapeutic agents directly to cancer cells, improving the therapeutic index of the drug and reducing systemic toxicity.

- **pH-Responsive Release:**

Quantum dots can also be engineered to release their drug payload in response to changes in pH, a feature particularly useful for tumor-targeted drug delivery. Tumor tissues typically exhibit a lower pH compared to normal tissues due to the rapid metabolism and acidic microenvironment. Quantum dots with pH-sensitive coatings or linkers can release their payload when exposed to this acidic environment.

- **Example:** In the case of cancer treatment, quantum dots can be loaded with chemotherapy drugs and conjugated with ligands that target tumor cells. The acidic tumor microenvironment triggers the release of the drug at the tumor site, enhancing the local drug concentration while minimizing damage to surrounding healthy tissue.

3. **Cancer Therapy:**

   Quantum dots have been extensively studied for their potential use in cancer therapy, particularly for targeted drug delivery. Some notable case studies include:

   - **Quantum Dots in Targeted Chemotherapy:**

     One study investigated the use of quantum dots conjugated with folic acid (a ligand targeting folate receptors, which are overexpressed in many cancers) for targeted delivery of chemotherapy drugs to cancer cells. The quantum dots effectively delivered the drugs to the tumor cells, resulting in higher cellular uptake, enhanced drug efficacy, and reduced side effects compared to free drug treatments.

   - **Quantum Dots for Imaging and Drug Delivery in Breast Cancer:**

     In another case study, quantum dots were used for dual purposes in breast cancer treatment—imaging and drug delivery. QDs functionalized with Her2-targeting antibodies were used to deliver paclitaxel, a chemotherapy drug, to Her2-positive breast cancer cells. The quantum dots were able to deliver the drug specifically to cancer cells, and their fluorescence enabled real-time imaging of tumor location and drug accumulation. This dual-functionality approach improved the targeting accuracy and therapeutic outcome while providing valuable diagnostic information.

   - **Quantum Dots in Combination Therapy for Lung Cancer:**

     Quantum dots were also explored for combination therapy in lung cancer. In this study, QDs were used to co-deliver both chemotherapy drugs and gene therapy agents to lung cancer cells. By combining the therapeutic effects of both drug types, the researchers were able to achieve a synergistic effect, resulting in improved tumor suppression and reduced drug resistance.

Challenges and Future Perspectives in Quantum Dots for Biomedical Applications

Quantum dots (QDs) have demonstrated immense potential in various biomedical applications, such as imaging, diagnostics, and targeted drug delivery. However, despite their advantages, there are several challenges that must be addressed before they can be widely adopted for clinical use. These challenges primarily revolve around toxicity, biocompatibility, regulatory approval, and the need for continuous innovation in QD design to enhance safety and efficacy.

1. **Toxicity and Biocompatibility Concerns:**

   One of the major concerns with quantum dots is their potential toxicity. The core materials of quantum dots, particularly cadmium-based QDs (e.g., cadmium selenide), are highly toxic to cells and tissues, raising concerns about their long-term use in vivo. These toxic

effects are often linked to the release of harmful ions or nanoparticles from the QD structure, which can accumulate in organs such as the liver, kidneys, and spleen, causing adverse health effects.

- **Heavy Metal Toxicity:**

  The use of heavy metals in QDs, such as cadmium, lead, and arsenic, poses significant risks to human health. As a result, non-toxic alternatives, such as zinc selenide (ZnSe), zinc sulfide (ZnS), and copper-based quantum dots, are being explored to minimize these risks. These alternative materials are designed to be biocompatible and reduce the release of toxic byproducts, making QDs safer for clinical applications.

- **Surface Functionalization to Reduce Toxicity:**

  Another strategy to address toxicity is surface functionalization. By coating quantum dots with biocompatible polymers (such as polyethylene glycol, PEG), the toxicity of QDs can be reduced, and their stability and solubility in biological environments are enhanced. PEGylation, for example, has been shown to reduce the immunogenicity of QDs and prolong their circulation time in the bloodstream, thus improving their biocompatibility and minimizing their toxic effects.

2. **Regulatory Hurdles and Clinical Translation:**

Despite the promising potential of quantum dots, their clinical translation faces significant regulatory challenges. The use of nanomaterials in medicine is subject to strict regulatory guidelines to ensure patient safety, and quantum dots are no exception. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), require rigorous testing of nanomaterials for their safety, efficacy, and long-term effects on human health before they can be approved for clinical use.

- **Lack of Standardized Protocols:**

  One of the key challenges in the regulatory approval of quantum dots is the lack of standardized protocols for their testing and evaluation. Different quantum dot formulations, surface modifications, and applications may require distinct testing approaches, making it difficult for regulatory bodies to establish universal guidelines. Additionally, the potential for QDs to interact with biological systems in unpredictable ways further complicates their regulatory assessment.

- **Long-Term Safety and Environmental Impact:**

  Long-term studies are required to evaluate the safety of quantum dots, particularly their biodegradation and accumulation in tissues over time. The potential environmental impact of QDs, especially those based on heavy metals, must also be considered. These concerns could delay the widespread clinical application of quantum dots until comprehensive safety data are available.

3. **Innovations in QD Design for Improved Safety and Efficacy:**

   To overcome the challenges associated with toxicity and regulatory concerns, significant innovations in quantum dot design are being explored. Researchers are working on developing safer, more efficient quantum dots that meet the stringent requirements of biomedical applications while minimizing potential risks.

   - **Development of Non-Toxic QDs:**

     One promising avenue is the development of non-toxic or "green" quantum dots. These include cadmium-free QDs, such as those based on indium, copper, or silicon. Cadmium-free quantum dots are not only less toxic but also exhibit better biocompatibility, making them more suitable for clinical applications. Silicon-based QDs, for example, offer a safer alternative as they are made from a widely available and biocompatible material.

   - **Surface Modification for Targeted Delivery:**

     Advances in surface modification techniques allow quantum dots to be functionalized with various biomolecules, including peptides, antibodies, and nucleic acids. These modifications enable targeted drug delivery to specific cells or tissues, increasing the therapeutic efficacy while reducing off-target effects. By improving the targeting specificity of quantum dots, researchers can reduce the required dose of therapeutic agents, minimizing toxicity while enhancing the treatment outcome.

   - **Biodegradable Quantum Dots:**


     Another innovative approach is the development of biodegradable quantum dots that can break down safely within the body. These QDs are designed to degrade into non-toxic byproducts after performing their intended function, eliminating the risk of long-term accumulation in tissues. Biodegradable materials, such as biodegradable polymers or peptides, are being incorporated into quantum dot designs to improve their safety profile.

   - **Hybrid Quantum Dots:**

     Hybrid quantum dots, which combine the properties of different materials, are also being explored. For example, combining organic materials with traditional semiconductor-based quantum dots can improve their biocompatibility while retaining their optical properties. These hybrid systems can offer better control over the release of drugs or imaging agents, further enhancing the safety and efficacy of quantum dots in therapeutic applications.

Naveed Rafaqat Ahmad is a researcher and practitioner with expertise in artificial intelligence applications, knowledge systems, and governance studies. His research focuses on the intersection of human decision-making and intelligent technologies, with particular emphasis on productivity enhancement, ethical risks, and accountability in digital work environments. He has published in peer-reviewed international journals on topics such as human–AI collaboration, public sector

reform, and institutional transparency. His work contributes to both academic scholarship and practical policy-oriented discussions on responsible and effective technology integration.



Summary:

Quantum dots have revolutionized biomedical imaging and drug delivery by providing high-resolution imaging capabilities and targeted therapeutic options. Their unique optical properties enable precise tracking of cellular processes and localization of therapeutic agents. Surface functionalization techniques have further enhanced their applicability by improving solubility, stability, and targeting specificity. However, the clinical translation of QD-based technologies is hindered by concerns regarding their toxicity and regulatory approval. Ongoing research focuses on developing biocompatible QDs and establishing standardized protocols for their use in clinical settings. The future of QDs in medicine looks promising, with potential applications in personalized therapy and early disease detection.

References:

Mattoussi, H., et al. (2000). *Self-assembly of CdSe–ZnS quantum dot nanocrystals in the presence of thiol-based ligands*. Journal of the American Chemical Society, 122(40), 11079-11086.

Alivisatos, A.P., et al. (2005). *Semiconductor nanocrystals: structure, properties, and band gap engineering*. Journal of Nanoscience and Nanotechnology, 5(6), 734-738.

Chan, W.C., & Nie, S. (1998). *Quantum dot bioconjugates for ultrasensitive nonisotopic detection*. Science, 281(5385), 2016-2018.

Gao, X., et al. (2004). *In vivo molecular and cellular imaging with quantum dots*. Current Opinion in Biotechnology, 15(1), 44-48.

Bruchez, M., et al. (1998). *Semiconductor nanocrystals as fluorescent biological labels*. Science, 281(5385), 2013-2016.

Smith, A.M., & Nie, S. (2010). *Quantum dots and biological assays*. Analytical and Bioanalytical Chemistry, 398(3), 537-543.

Zhang, Y., et al. (2012). *Quantum dots in drug delivery systems: The innovative platforms for targeted delivery of therapeutic agents*. Journal of Nanomedicine, 7(8), 1051-1061.

Yang, H., et al. (2015). *Application of quantum dots for cancer imaging and therapy*. Nanomedicine: Nanotechnology, Biology, and Medicine, 11(5), 1239-1248.

Lou, Y., et al. (2014). *Quantum dot-based drug delivery systems for cancer treatment*. Nanomedicine: Nanotechnology, Biology, and Medicine, 10(3), 547-558.

Li, L., et al. (2017). *Quantum dots in drug delivery and biomedical imaging*. International Journal of Nanomedicine, 12, 3871-3889.

Yu, M., et al. (2017). *Surface modification of quantum dots for biomedical applications*. Journal of Materials Chemistry B, 5(13), 2471-2480.

Zheng, X., et al. (2012). *Quantum dot-based drug delivery systems*. Journal of Materials Chemistry, 22(1), 23-30.

Peng, X., et al. (2000). *Epitaxial growth of highly luminescent CdSe/CdS core/shell nanocrystals with photostability and electronic accessibility*. Journal of the American Chemical Society, 122(22), 4701-4706.

Wang, X., et al. (2007). *Quantum dots in biomedical applications: Opportunities and challenges*. Journal of Controlled Release, 120(3), 323-329.

Qian, H., et al. (2010). *Quantum dots as novel drug delivery systems for targeted chemotherapy*. International Journal of Nanomedicine, 5, 1171-1182.

Ma, X., et al. (2012). *Quantum dot-based drug delivery systems for cancer therapy*. Journal of Nanotechnology, 23, 1-10.

Zhang, X., et al. (2016). *The role of quantum dots in targeted drug delivery*. Drug Delivery, 23(3), 1234-1245.

Rao, J., & Yao, H. (2013). *Quantum dots for in vivo molecular imaging and therapy*. Journal of Controlled Release, 171(3), 305-316.

Liu, J., et al. (2011). *Quantum dot-based drug delivery systems and their use in drug delivery*. Molecular Pharmaceutics, 8(5), 1731-1741.

Wang, T., et al. (2016). *Quantum dots in drug delivery and cancer treatment: Current trends and future perspectives*. Journal of Nanoscience and Nanotechnology, 16(1), 1-9.

Ahmad, N. R. (2024). *Human–AI collaboration in knowledge work: Productivity, errors, and ethical risk*. *Journal of Knowledge Systems and Digital Ethics, 6*(2), Article 9250. https://doi.org/10.52152/6q2p9250